trial · primary record
Actinium Ac 225-DOTA-Daratumumab
Recurrent Plasma Cell Myeloma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2027-03-23 |
| Primary endpoint | Incidence of dose-limiting toxicities (DLTs) |
| Registry ID | NCT05363111 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:47.305Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05363111
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Actinium Ac 225-DOTA-Daratumumab · compound